Ad-hoc | 12 February 2003 08:00

Eckert & Ziegler AG english

Eckert & Ziegler Expects a Balanced Result for 2002 Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Eckert & Ziegler Expects a Balanced Result for 2002 and income increase in 2003 despite High Biotechnology Investments Berlin, 12 Feb. 2003 – According to preliminary evaluations, the Eckert & Ziegler AG, a leading European specialist for weakly radioactive medical and industrial products, has been able to achieve an approximately balanced result in 2002, despite high extraordinary expenditures of EUR 3.3 mil. for biotechnological development projects. The sales volume remained persisted at the previous year’s level of EUR 32 mil., due to non-recurring effects in the previous year and to the weak exchange rate for the dollar. At the turn of the year 2002-2003, liquid funds had increased to EUR 8.5 mil., or some EUR 300,000 more than on 31 Dec. 2001, despite a dividend payout in May 2002. Due to the unfavorable dollar exchange rate and dropping sales in the area of cardiovascular radiation sources, the Executive Board does not expect sales increases yet in the current fiscal year. An increase in the result per share to about EUR 0.30 is expected, however. Contributing to this are, for example, a recently concluded bulk order for the delivery of prostate-gland cancer products and a production line, as well as a reduction of expenses in biotechnological developments. In the latter area of business, animal tests of the pilot product Pankomab have now confirmed that in the direct comparison, the antibody, which targets a pancarcinomic antigen, accumulates in tumors better than competing products. The definitive presentation of the data by NEMOD Immuntherapie AG, in which Eckert & Ziegler AG has a share, is expected in approximately mid-March. The Executive Board of Eckert & Ziegler AG has applied to the German Stock Exchange for admission to the Prime Standard. The Board of Directors Eckert & Ziegler AG, Karolin Riehle, Investor Relations http://www.ezag.com, Tel.: +49 (0) 30 / 94 10 84-138 end of ad-hoc-announcement (c)DGAP 12.02.2003 ——————————————————————————– WKN: 565970; ISIN: DE0005659700; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover und Stuttgart 120800 Feb 03